Research analysts covering Cellyan Biotechnology.
Recent press releases and 8-K filings for HKPD.
Cellyan Biotechnology Receives Nasdaq Bid Price Deficiency Notice
HKPD
Delisting/Listing Issues
- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) received a Nasdaq notification letter on January 12, 2026, indicating non-compliance with the minimum bid price requirement.
- The company's class A ordinary shares traded below US$1.00 for 30 consecutive business days from November 26, 2025, to January 9, 2026.
- HKPD has 180 calendar days, until July 13, 2026, to regain compliance by having its closing bid price at or above US$1.00 for at least ten consecutive business days.
- The notification does not immediately affect the trading of the company's shares on Nasdaq.
- If compliance is not regained by July 13, 2026, the company may be eligible for an additional 180-day grace period, provided it meets other listing standards and intends to cure the deficiency, potentially through a reverse share split.
Jan 16, 2026, 9:30 PM
Cellyan Biotechnology Co., Ltd Receives Nasdaq Bid Price Deficiency Notice
HKPD
Delisting/Listing Issues
- Cellyan Biotechnology Co., Ltd (HKPD) received a notification from Nasdaq on January 12, 2026, for failing to meet the minimum bid price requirement.
- The company's Class A ordinary shares traded below $1.00 for 30 consecutive business days from November 26, 2025, through January 9, 2026.
- HKPD has a compliance period until July 13, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.
- The notification does not result in immediate delisting, and the shares will continue to trade under the symbol "HKPD".
Jan 16, 2026, 9:29 PM
Hong Kong Pharma Digital Technology Holdings Limited Announces 2025 Annual Meeting Results
HKPD
Proxy Vote Outcomes
Share Buyback
Board Change
- Hong Kong Pharma Digital Technology Holdings Limited's shareholders approved a company name change to Cellyan Biotechnology Co., Ltd.
- Shareholders also approved significant changes to the company's capital structure, including an increase in authorized share capital from US$100,000 to US$1,000,000, the re-designation of shares into Class A (1 vote per share) and Class B (50 votes per share) ordinary shares, and the implementation of a reverse share split and share consolidation at a ratio between one-for-ten and one-for-one hundred.
- The company received approval to repurchase 7,150,000 Class A Ordinary Shares from TUTU Business Services Limited at a nominal price of US$1, funded by the issuance of Class B Ordinary Shares.
Dec 17, 2025, 9:30 PM
Hong Kong Pharma Digital Announces 2025 Annual Meeting Results
HKPD
Proxy Vote Outcomes
Share Buyback
Board Change
- Stockholders of Hong Kong Pharma Digital Technology Holdings Limited passed all proposals at the 2025 annual meeting held on December 12, 2025.
- Key approvals included the re-election of five directors and the ratification of Onestop Assurance PAC as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
- The company's authorized share capital will be increased from US$100,000 to US$1,000,000, and ordinary shares will be re-designated into Class A and Class B ordinary shares.
- Stockholders approved a Reverse Share Split and Share Consolidation, and the repurchase of 7,150,000 Class A Ordinary Shares.
- The company's name will be changed from "Hong Kong Pharma Digital Technology Holdings Limited" to "Cellyan Biotechnology Co., Ltd".
Dec 17, 2025, 9:30 PM
Hong Kong Pharma Digital Technology Holdings Limited announces management changes, including new CEO and CFO appointments
HKPD
CEO Change
CFO Change
Management Change
- Hong Kong Pharma Digital Technology Holdings Limited announced significant management changes effective October 6, 2025, including the resignations of its CEO, Executive Director, and CFO, and the appointment of a new CEO, CFO, and Chief Strategy Officer.
- Mr. Chenyu Liang was appointed as Director and Chief Executive Officer, Ms. Shu Liu as Chief Financial Officer, and Mr. Zifeng Wang as Chief Strategy Officer.
- The new CEO, Mr. Liang, and CFO, Ms. Liu, will each receive an annual base salary of HKD100,000, while the new CSO, Mr. Wang, will receive HKD70,000.
- Their employment agreements have an initial term of one year and include severance provisions, such as a cash payment of three months of base salary upon termination without cause.
Oct 6, 2025, 10:47 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more